SCTX
NasdaqGMScribe Therapeutics Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 28 recent filings. 21 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
AH Bio Fund II, L.P. 10% Owner | Conversion | 2.05M | — | — | 2026-07-27 |
AH Bio Fund II, L.P. 10% Owner | Conversion | 697.65K | — | — | 2026-07-27 |
AH Bio Fund II, L.P. 10% Owner | Buy (open market) | 333.33K | $15.00 | $4,999,995.00 | 2026-07-27 |
AH Bio Fund II, L.P. 10% Owner | Conversion | 12.15M | $0.00 | — | 2026-07-27 |
AH Bio Fund II, L.P. 10% Owner | Conversion | 4.13M | $0.00 | — | 2026-07-27 |
GORDON CARL L Director | Conversion | 348.83K | — | — | 2026-07-27 |
GORDON CARL L Director | Buy (open market) | 1M | $15.00 | $15,000,000.00 | 2026-07-27 |
GORDON CARL L Director | Conversion | 2.07M | $0.00 | — | 2026-07-27 |
ORBIMED ADVISORS LLC Director | Conversion | 348.83K | — | — | 2026-07-27 |
ORBIMED ADVISORS LLC Director | Buy (open market) | 1M | $15.00 | $15,000,000.00 | 2026-07-27 |
ORBIMED ADVISORS LLC Director | Conversion | 2.07M | $0.00 | — | 2026-07-27 |
Doudna Jennifer A 10% Owner | Conversion | 12.51K | — | — | 2026-07-27 |
Doudna Jennifer A 10% Owner | Conversion | 74.09K | — | — | 2026-07-27 |
Aghazadeh Behzad Director, 10% Owner, See Remarks | Buy (open market) | 2.33M | $15.00 | $34,999,995.00 | 2026-07-24 |
Aghazadeh Behzad Director, 10% Owner, See Remarks | Buy (open market) | 50K | $22.31 | $1,115,500.00 | 2026-07-24 |
Aghazadeh Behzad Director, 10% Owner, See Remarks | Buy (open market) | 7.91K | $18.25 | $144,266.25 | 2026-07-28 |
Staahl Brett 10% Owner | Grant / award | 4.76K | $0.00 | — | 2026-03-13 |
Staahl Brett 10% Owner | Grant / award | 19.39K | $0.00 | — | 2026-07-23 |
Staahl Brett 10% Owner | Grant / award | 19.39K | $0.00 | — | 2026-07-23 |
Lucas Svetlana Chief Business Officer | Buy (open market) | 3K | $15.00 | $45,000.00 | 2026-07-23 |
Lucas Svetlana Chief Business Officer | Grant / award | 9.55K | $0.00 | — | 2026-03-13 |
Lucas Svetlana Chief Business Officer | Grant / award | 109.43K | $0.00 | — | 2026-07-23 |
Lucas Svetlana Chief Business Officer | Grant / award | 109.43K | $0.00 | — | 2026-07-23 |
Oakes Benjamin L. Director, President, CEO, Chairman of the Board | Grant / award | 12.97K | $0.00 | — | 2026-03-13 |
Oakes Benjamin L. Director, President, CEO, Chairman of the Board | Grant / award | 264.78K | $0.00 | — | 2026-07-23 |
Oakes Benjamin L. Director, President, CEO, Chairman of the Board | Grant / award | 429.6K | $0.00 | — | 2026-07-23 |
GORDON CARL L Director | Grant / award | 14.73K | $0.00 | — | 2026-07-23 |
Watson James Dean Director | Grant / award | 14.73K | $0.00 | — | 2026-07-23 |
Source: SEC EDGAR Forms 4/4A (CIK 1853921). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$SCTX open market! 👀
$SOFI - #DDAmanda Chart. Bullish or bearish? Watching these too: $RAY.X $SCTX $TC Best Stock Screener + Dilution Tracker: https://DDAmanda.com
Another DDAmanda find: $AMIX +73% - Caught it before the crowd showed up. Previously flagged: $NDLS $LVWR $SCTX Which one are you watching next:: https://DDAmanda.com
$SCTX
$SCTX A private placement of nearly 2.4 million shares held by a company director—worth $36 million—was announced; nobody puts up $36 million without having insider information.
$SCTX
Opening Day: Scribe Therapeutics makes strong trading debut - $SCTX - https://thefly.com/SCTX
IPO Winners & Losers: Jersey Mike's, Bubble Baths, and Biotech Wins $JMKE $REF $SCTX $IPO #IPO https://zpr.io/RZDKTieFGQhX
$DFNS showing up on DDAmanda. Also found: $LVWR $OMH $SCTX Best Stock Screener - Dilution Tracker: https://DDAmanda.com
$LGHL is running - where does it stop? DDAmanda Chart Also found early: $OMH $NIPG $SCTX Anyone watching this one? https://DDAmanda.com
Top Gainers $STAK $LVWR $WLDS $NIPG $SCTX
Top Gainers $STAK $LVWR $WLDS $NIPG $SCTX
Latest news
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
Top Midday Gainers
Sector Update: Healthcare Stocks Rise in Afternoon Trading
Scribe Therapeutics Prices Upsized IPO at $15 per Share
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
Update: Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Through IPO
Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Stake Through IPO
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.